The medtech hybrid company CEO manages a business that operates in two regulatory universes simultaneously. On the pharmaceutical side, FDA’s Center for Drug Evaluation and Research (CDER) governs drug development, approval, and post-market surveillance. On the device side, FDA’s Center for Devices and Radiological Health (CDRH) governs 510(k) clearances, premarket approvals, and device post-market obligations. Each center has its own scientific culture, review timelines, guidance documents, and expectations for sponsor engagement. A company with products in both categories cannot simply apply pharmaceutical development discipline to devices or vice versa.
Medtech hybrid company CEO time management begins with accepting that this regulatory duality creates a permanently expanded set of obligations at the top of the organization. The CEO cannot fully delegate regulatory strategy to a single regulatory affairs function and expect coherent, integrated decision-making. Both pathways require CEO-level understanding and, at key junctures, CEO-level engagement.
The Structural Challenge of Dual Regulatory Pathways
CDER and CDRH differ in ways that are substantive and operationally significant. CDER’s drug approval process, anchored in the NDA or BLA framework, requires large randomized controlled trials with mortality or morbidity endpoints, extensive pharmacokinetic and pharmacodynamic characterization, and a comprehensive safety database across thousands of patients. The timeline from IND to NDA approval for a novel drug averages 10 to 15 years.
CDRH’s device approval process, anchored in the 510(k) or PMA framework, often emphasizes substantial equivalence to predicate devices, bench testing, and targeted clinical studies. PMA approval for a novel high-risk device typically requires two to five years of post-IDE clinical data. The scientific standards are different, the evidence requirements are different, and the regulatory review interactions are conducted with fundamentally different agency cultures.
For the medtech hybrid CEO, this means managing two distinct regulatory strategies, two distinct regulatory teams, and two distinct FDA relationships. The CEO must personally understand both frameworks well enough to evaluate regulatory strategy recommendations, identify where the pathways create organizational confusion, and ensure that the company is not inappropriately applying device development discipline to drug programs or vice versa.
A practical commitment: the medtech hybrid CEO should invest three to four hours per month in direct regulatory strategy review for each product category, separate from the combined organization reviews. This ensures that neither the drug nor device regulatory program is systematically under-prioritized.
Combination Product Governance: The CEO’s Decision Point
Many medtech hybrid companies develop combination products: drug-device combinations, biologic-device combinations, or diagnostic-drug combinations where the regulatory pathway involves both CDER and CDRH. FDA’s Office of Combination Products (OCP) assigns primary jurisdiction to one center but both centers may be involved in review.
Combination product strategy is one of the most consequential CEO-level decisions in a hybrid company. The choice of primary mode of action, the regulatory pathway designation request, the clinical development design for the combination, and the labeling strategy all involve tradeoffs that affect development timeline, intellectual property, reimbursement classification, and competitive positioning. These are not decisions that can be made below the CEO level without CEO guidance on strategic priorities.
The OCP Request for Designation process, which formally assigns a combination product to CDER, CDRH, or CBER primary jurisdiction, should involve CEO review before submission. The CEO’s understanding of the company’s strategic intent for the product, the competitive positioning, and the commercial infrastructure needed for launch should inform the pathway choice. The FDA’s combination products regulatory guidance provides the regulatory framework that the CEO and regulatory leadership should jointly understand.
Reimbursement Navigation: Two Different Systems
Pharmaceutical and device products are reimbursed under fundamentally different systems in the United States. Drug reimbursement runs primarily through medical benefit and pharmacy benefit structures, with formulary placement determined by PBMs and payer pharmacy committees. Device reimbursement runs through Medicare’s DMEPOS benefit, the hospital outpatient prospective payment system (OPPS), the inpatient prospective payment system (IPPS), and physician fee schedule coverage, with coverage decisions made by CMS’s Coverage and Analysis Group or by Medicare Administrative Contractors.
The medtech hybrid CEO manages two distinct reimbursement strategies requiring two different commercial capabilities. The pharmaceutical commercial organization must navigate PBM formulary management, prior authorization management, and specialty pharmacy distribution. The device commercial organization must navigate hospital supply chain, physician purchasing decisions, CMS coverage determination processes, and coding strategy (HCPCS/CPT code development).
These capabilities are genuinely different. The skill sets required, the account management structures, and the reimbursement policy advocacy activities are distinct. A medtech hybrid company that tries to deploy a single commercial organization across both product categories will typically underperform in one or both.
The CEO’s role in reimbursement navigation is strategic: setting the resource allocation philosophy between drug and device commercial infrastructure, ensuring that reimbursement strategy for each product category is governed by leaders with the right expertise, and personally engaging with CMS and major payer leadership on reimbursement policy matters that affect the portfolio.
Setting Reimbursement Strategy Priorities
One of the most demanding time management challenges for the medtech hybrid CEO is governing reimbursement strategy across two systems simultaneously. When drug and device reimbursement challenges arise in the same quarter, the CEO must make allocation decisions about senior commercial leadership attention and advocacy investment.
A structured monthly reimbursement review, covering both drug and device reimbursement metrics and policy developments, provides the CEO with the information needed to make these allocation decisions. The review should include: formulary status and trend for drug products, CMS coverage determination status and MAC coverage policy developments for device products, payer policy changes affecting either category, and advocacy priorities for the commercial affairs and government affairs teams.
Clinical Infrastructure: Managing Two Evidence Generation Models
Pharmaceutical clinical development operates through INDs, IRB-approved protocols, clinical research sites with trained investigators, and ICH-compliant data management. Device clinical development often involves different site types, different investigator training requirements, registry-based evidence generation, and real-world data approaches that are less central to traditional drug development.
The medtech hybrid company CEO managing clinical infrastructure across both categories faces organizational questions that pharmaceutical-only or device-only companies do not encounter:
Shared clinical operations. Can the clinical operations organization support both drug and device trial types, or do the differences in protocol design, site requirements, and data standards require separate functions? In most organizations above a certain size, separate functions with shared governance are more effective than attempted full integration.
Data standards alignment. CDER and CDRH have different expectations for clinical data standards, electronic submissions, and statistical analysis plans. The CEO must ensure that the data management and biostatistics organizations have expertise aligned with each regulatory pathway.
Medical affairs alignment. Medical affairs for pharmaceutical products (MSL deployment, publication strategy, CME governance) differs substantially from medical affairs for device products (surgeon/physician training, proctoring programs, clinical peer-to-peer). These activities require different capabilities and the CEO must invest in both.
For context on managing complex multi-regulatory-pathway portfolios, see pharma CEO multiple therapeutic areas.
Commercial Organization Structure: The CEO’s Architecture Decision
The most consequential organizational design decision the medtech hybrid CEO makes is how to structure the commercial organization. Options range from a fully unified commercial organization with product-specific sales teams to fully separate pharmaceutical and device commercial organizations with independent leadership.
Each structure has advantages and costs. Full integration creates cost efficiency and unified customer relationship management but risks under-specialization in both drug and device commercial disciplines. Full separation preserves commercial expertise but creates higher overhead and potential misalignment on accounts where the company has both drug and device relationships.
Most mature medtech hybrid companies land at a structure with separate commercial leadership for drug and device businesses, reporting to a single Chief Commercial Officer who provides portfolio coordination and shared services oversight. The CEO’s role is to ensure this CCO has deep expertise across both models, not just one, and to personally arbitrate strategic commercial decisions that affect both businesses.
Time Architecture for the Medtech Hybrid CEO
A practical time architecture for medtech hybrid company CEO time management:
Weekly anchors. A 90-minute weekly portfolio review with the CMO and CSO covering both drug and device development activities. A standing weekly commercial review alternating between drug and device commercial updates on a biweekly cycle, with a monthly combined commercial review.
Monthly commitments. Separate regulatory strategy reviews for drug and device pipelines (three to four hours each). A combined reimbursement strategy review. A combination product governance review if active combination programs exist. A board-ready portfolio update covering both business lines.
Quarterly investments. Senior FDA engagement across both CDER and CDRH: the CEO should be known and credible to senior officials at both centers. A strategic portfolio review covering development prioritization, commercial resource allocation, and regulatory pathway decisions for the coming 12 months. CMS engagement on reimbursement policy matters affecting the device portfolio.
Organizational health reviews. Quarterly talent reviews specifically addressing whether the organization has the specialized expertise required in each of the functional areas where drug and device capabilities diverge: regulatory affairs, clinical operations, medical affairs, commercial.
Executive Support for the Medtech Hybrid Calendar
The medtech hybrid CEO’s calendar complexity is greater than that of single-modality pharmaceutical or device CEOs. The EA supporting this role must maintain forward visibility across both CDER and CDRH regulatory calendars, CMS coverage determination timelines, ACEP and other payer policy meeting schedules, and the dual clinical program milestone calendars.
Effective EA support in this context includes: managing the regulatory and commercial review cadence so that drug and device programs receive equivalent attention rather than allowing one modality to default to primary focus, ensuring that senior FDA engagement at both centers is calendared proactively, and flagging conflicts between the dual-track obligations before they become calendar crises.
Conclusion
Medtech hybrid company CEO time management demands a genuinely dual-track approach to regulatory strategy, reimbursement navigation, and clinical and commercial infrastructure. CEOs who succeed in this role invest the time to develop real working knowledge of both CDER and CDRH regulatory frameworks, build organizational capacity that respects the genuine differences between pharmaceutical and device disciplines, and govern the combined portfolio with the rigor that each modality independently requires. The hybrid model creates operational complexity: the executives who thrive in it convert that complexity into competitive advantage by being more capable than either pure-play pharmaceutical or pure-play device competitors at managing regulatory and commercial complexity.
Related Reading
For further context, explore Time Management for Animal Health Pharma CEOs and Biologics CEO Time Management: Navigating Manufacturing Complexity.